2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-

PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1

BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers.

pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1].

0.006-0.10 μm

1) Chupak?et al. (2015), Compounds Useful as Immunomodulators; WO2015/034820